ContributorsPublishersAdvertisers

Raghav

onclive.com

Dr. Raghav on the Utilization of ctDNA in mCRC

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer. Kanwal P.S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center, discusses on the utilization of circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).
CANCER
onclive.com

Dr. Raghav on Potential Combinations With Trastuzumab Deruxtecan in HER2+ CRC

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer. Kanwal P.S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center, discusses potential combinations with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive colorectal cancer (CRC).
CANCER
RELATED CHANNELS
onclive.com

Dr. Raghav on the Rationale for the DESTINY-CRC02 Trial in HER2+ mCRC

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer. Kanwal P.S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial (NCT04744831) in HER2-overexpressing metastatic colorectal cancer (mCRC).
CANCER
onclive.com

Dr. Raghav on Treatment Considerations in Metastatic CRC

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer. Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment considerations in metastatic colorectal cancer (mCRC). mCRC is managed with a wide variety of...
CANCER
onclive.com

Dr. Raghav on Treatment Considerations With Regorafenib and TAS-102 in CRC

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer. Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the...
CANCER
RELATED PEOPLE
onclive.com

Dr. Raghav on Regorafenib Dose Optimization in CRC

Kanwal Raghav, MBBS, MD, discusses optimal dosing strategies for regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses optimal dosing strategies for regorafenib (Stivarga) in patients with colorectal cancer (CRC).
CANCER
onclive.com

Dr. Raghav on First-Line Treatment Options in CRC

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer. Kanwal Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses first-line treatment options for patients with colorectal cancer (CRC). The arsenal for treating...
CANCER
onclive.com

Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses adjusting dosing with regorafenib (Stivarga) in patients with colorectal cancer (CRC).
CANCER
onclive.com

Dr. Raghav on Selecting Treatment with TAS-102 vs Regorafenib in CRC

Kanwal Raghav, MBBS, MD, discusses the process for selecting between treatment with trifluridine and tipiracil vs regorafenib in patients with colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the process for selecting between treatment with trifluridine and tipiracil (Lonsurf; TAS-102) vs regorafenib (Stivarga) in patients with colorectal cancer (CRC).
CANCER
onclive.com

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer. Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the utility of chemotherapy-free intervals in colorectal cancer (CRC).
CANCER